177 related articles for article (PubMed ID: 34993886)
1. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
2. Parathyromatosis and the challenge of treatment.
Daphnis E; Stylianou K; Katsipi I; Stratigis S; Karamitopoulou E; Karkavitsas N; Kyriazis J
Am J Kidney Dis; 2006 Sep; 48(3):502-5. PubMed ID: 16931226
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
5. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
6. Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic.
Alfadhli EM
Clin Ther; 2021 Apr; 43(4):711-719. PubMed ID: 33752899
[TBL] [Abstract][Full Text] [Related]
7. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
[TBL] [Abstract][Full Text] [Related]
9. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Leere JS; Karmisholt J; Robaczyk M; Lykkeboe S; Handberg A; Steinkohl E; Brøndum Frøkjær J; Vestergaard P
Lancet Diabetes Endocrinol; 2020 May; 8(5):407-417. PubMed ID: 32333877
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.
Cruzado JM; Moreno P; Torregrosa JV; Taco O; Mast R; Gómez-Vaquero C; Polo C; Revuelta I; Francos J; Torras J; García-Barrasa A; Bestard O; Grinyó JM
J Am Soc Nephrol; 2016 Aug; 27(8):2487-94. PubMed ID: 26647424
[TBL] [Abstract][Full Text] [Related]
12. Parathyromatosis and recurrent hyperparathyroidism.
Lentsch EJ; Withrow KP; Ackermann D; Bumpous JM
Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):894-6. PubMed ID: 12925351
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function.
Nguyen S; Gosmanova EO; Gosmanov AR
J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism.
Moreno P; Coloma A; Torregrosa JV; Montero N; Francos J; Codina S; Manonelles A; Bestard O; García-Barrasa A; Melilli E; Cruzado JM
Clin Transplant; 2020 Aug; 34(8):e13988. PubMed ID: 32438479
[TBL] [Abstract][Full Text] [Related]
16. Recurrent primary hyperparathyroidism due to Type 1 parathyromatosis.
Jain M; Krasne DL; Singer FR; Giuliano AE
Endocrine; 2017 Feb; 55(2):643-650. PubMed ID: 27743301
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Faiq S; Lavelle K; Hu T; Shoback D; Ku G
BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
[TBL] [Abstract][Full Text] [Related]
18. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
[TBL] [Abstract][Full Text] [Related]
20. A pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy.
Edling KL; Korenman SG; Janzen C; Sohsman MY; Apple SK; Bhuta S; Yeh MW
Endocr Pract; 2014 Feb; 20(2):e14-7. PubMed ID: 24013984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
